Company: MDXG
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001376339-25-000048
Chunk: 37

Company: MIMEDX GROUP, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 37
---
 in June 2025.

<div align='center'>19</div>

Launched MIMEDX Connect, E-Commerce and Account Management Platform

In March 2024, the Company announced the launch of MIMEDX Connect, a first-of-its-kind online product ordering and account management portal available to its customers through the Company’s website. MIMEDX Connect provides secure access for customers to place and track orders, pay invoices, submit insurance verification requests, and review pricing and relevant documentation. To date, over 1,000 of our customers have started using MIMEDX Connect, which we view as an important offering to support our strategic objective associated with further building our customer intimacy and reducing customer churn, thereby increasing the lifetime value of each customer.

Expanded Portfolio with First Xenograft Product Offering, HELIOGEN

In March 2024, the Company announced an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement for Regenity Biosciences’ 510(k)-cleared, bovine-derived collagen matrix product, which we named HELIOGEN. The partnership with Regenity Biosciences will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions.

Promoted Kimberly Maersk-Moller to Chief Commercial Officer

In June 2024, the Company promoted Kimberly Maersk-Moller to Chief Commercial Officer; Ms. Maersk-Moller had served as the Company’s Senior Vice President of Sales since August 2020. Ms. Maersk-Moller boasts nearly three decades of experience in sales leadership roles, having successfully executed strategic growth plans for leading advanced wound care companies, including 3M and its subsidiaries Acelity and KCI.

High Profile Publications in Nature – Scientific Reports and The New York Times

In July 2024, the Company announced the publication of a peer reviewed study in Nature focused on surgical applications for two of its PURION® processed placental allografts. The study characterizes a potential mechanism by which placental allografts modulate the occurrence of scarring and fibrosis in surgical procedures. Both dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) demonstrated modulation of collagen production, deposition, and maturation in support of the hypothesis that amniotic membranes may function to interrupt pathological fibrosis and restore tissue homeostasis.

In October 2024